PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. With our ATTEC (autophagosome-tethering compound) technology, we are developing a novel class of small molecule degraders capable of binding a diverse array of substrates to the autophagy pathway including proteins, aggregates, lipids, organelles and pathogens. PAQ’s research advances in this important new class of degradation therapies have the potential to fundamentally transform drug discovery and development.
Location: United States, Massachusetts, Cambridge
Employees: 1-10
Total raised: $69M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | MRL Ventur... | mrlv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.05.2025 | Series B | $39M | - |
| - | Series A | $30M | - |
Mentions in press and media 10
| Date | Title | Description |
| 26.01.2026 | PAQ Therapeutics Raises Series B Extension; Brings Total Series B to $77M | PAQ Therapeutics, a Burlington, MA-based clinical-stage oncology company developing targeted protein degradation therapies for KRAS-driven cancers, raised a Series B extension funding. The raise brought the total of Series B to $77M. It fol... |
| 12.05.2025 | PAQ Therapeutics: A New Dawn in Cancer Treatment with $39 Million Series B Funding | In the relentless battle against cancer, a new warrior has emerged. PAQ Therapeutics, a biotechnology company based in Burlington, Massachusetts, has successfully raised $39 million in Series B funding. This significant financial boost is n... |
| 11.05.2025 | PAQ Therapeutics: $39 Million Series B Raised To Address KRAS-Driven Cancers With High Unmet Need | PAQ Therapeutics, a biotechnology company that is developing best- and first-in-class KRAS degraders for patients with lethal cancers lacking effective treatment options, today announced the completion of its $39 million Series B funding. T... |
| 07.05.2025 | PAQ Therapeutics Raises $39M in Series B Financing | PAQ Therapeutics, a Burlington, MA-based biotechnology company developing KRAS degraders, raised $39M in Series B funding. The round was led by Bayland Capital and MRL Ventures Fund (MRLV), with participation from Johnson & Johnson Inno... |
| 02.05.2025 | PAQ Therapeutics Announces $39M Series B Financing | BURLINGTON, MA, PAQ Therapeutics, a biotechnology company, announced the completion of its $39 million Series B funding. >> Click here for more funding data on PAQ Therapeutics >> To export PAQ Therapeutics funding data to PDF ... |
| 09.09.2021 | Roche to buy up diagnostics partner TIB Molbiol; PAQ to partner with Insilico | Roche is buying its longtime partner biotech TIB Molbiol Group, the Swiss drugmaker announced Thursday. While the financial details of the arrangement were not disclosed, the two companies have collaborated for more than... |
| 15.07.2021 | PAQ Therapeutics emerges with $30M series A for autophagy-based treatments | PAQ Therapeutics hopes to break into the emerging field of autophagy, which is essentially the cell's garbage disposal, to complement or compete against the broader protein degradation field. The Cambridge, Massachusetts-based biotech revea... |
| - | PAQ Therapeutics scores $30M to unleash “Pac-Man” drugs on neuro disease | Few biotech executives explain their experimental therapies by comparing them to video games. Nan Ji, president and CEO of PAQ Therapeutics, does so enthusiastically, and by using a 40-year-old game at that. In the 1980s, Pac-Man was an arc... |
| - | PAQ Therapeutics | “Our team is united by a visionary goal – to pioneer a new approach to restore health and cure disease through the power of autophagy.” |
| - | PAQ Therapeutics | “PAQ Therapeutics is developing KRAS degraders for deadly cancers without good treatment options.” |